Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases.
The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovant™, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aeroderm™, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
At
Aerovance, we recognize employees are the 